Mayne Pharma Group Limited is pleased to announce a new strategic collaboration with GoodRx, a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States. In addition, the initiative is focused on improving access to and raising awareness of available birth control methods.GoodRx has millions of visitors who come to the site each month looking for ways to save on their medications and more than 750,000 healthcare providers (HCPs) have used the platform since June 2021 to help their patients access their prescriptions. By combining GoodRx's reach with Mayne Pharma's novel contraceptive, which IQVIA notes is the fastest growing branded contraceptive in 2022 based on total prescriptions dispensed[1], this program will help further engage consumers and increase access for NEXTSTELLIS®. It will also build awareness among HCPs, over 4,000 of whom have already written prescriptions for the product.
MYX Price at posting:
$3.08 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)